The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population

Journal of the Neurological Sciences

Volumn 258, Issue 1-2, 2007, Pages 69-74

  Silva, Ana Martins ^a   Pereira, Clara ^b   Bettencourt, Andreia ^b   Carvalho, Cláudia ^b,c   Couto, Ana Rita ^d   Leite, Maria Isabel ^a   Marta, Mónica ^a   Freijo, Marta ^a   Costa, Paulo Pinho ^b,c   Mendonça, Denisa ^b   Monteiro, Luís ^a   Armas, Jácome Bruges ^d   Martins, Berta ^b,c  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c NATIONAL INSTITUTE OF HEALTH   (Portugal)

^d Hospital Santo Espirito de Angra do Heroesmo   (Portugal)

Author keywords

Class II; DRB1*15; HLA; Multiple sclerosis; Portugal

Indexed keywords

HLA DR ANTIGEN;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MULTIPLE SCLEROSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PORTUGAL; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; SURVIVAL RATE;

ADOLESCENT; ADULT; ALLELES; CASE-CONTROL STUDIES; CHILD; DISABILITY EVALUATION; DISEASE SUSCEPTIBILITY; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENOTYPE; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; ODDS RATIO; PORTUGAL; PROBABILITY; SURVIVAL ANALYSIS;

EID: 34249880485     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.02.033     Document Type: Article

References (42)

1. Dyment D.A., Ebers G.C., and Sadovnick A.D. Genetics of multiple sclerosis. Lancet Neurol 3 2 (2004) 104-110
2. Jersild C., Svejgaard A., and Fog T. HL-A antigens and multiple sclerosis. Lancet 1 7762 (1972) 1240-1241
3. De Moerloose P.H., Jeannet M., Martins-da-Silva B., Werner-Favre C., Rohr J., and Gauthier G. HLA-DRW antigens and multiple sclerosis. Schweiz Arch Neurol Neurochir Psychiatr 123 1 (1978) 51-61
4. A meta-analysis of whole genome linkage screens in multiple sclerosis. J Neuroimmunol 143 1-2 (2003) 39-46
5. Hillert J. Multiple sclerosis: postlinkage genetics. Clin Neurol Neurosurg 108 3 (2006) 220-222
6. Martins Silva B., Thorlacius T., Benediktsson K., Pereira C., Fossdal R., Jonsson H.H., et al. A whole genome association study in multiple sclerosis patients from north Portugal. J Neuroimmunol 143 1-2 (2003) 116-119
7. Masterman T., Ligers A., Olsson T., Andersson M., Olerup O., and Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 48 2 (2000) 211-219
8. *1501) heterodimer. Tissue Antigens 50 1 (1997) 15-22
9. Pina M.A., Ara J.R., Lasierra P., Larrad L., and Modrego P.J. Major histocompatibility complex class II alleles and the course and outcome of MS. Neurology 52 9 (1999) 1923-1924
10. McDonnell G.V., Mawhinney H., Graham C.A., Hawkins S.A., and Middleton D. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. J Neurol Sci 165 1 (1999) 77-83
11. Oksenberg J.R., Barcellos L.F., Cree B.A., Baranzini S.E., Bugawan T.L., Khan O., et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 74 1 (2004) 160-167
12. Stewart G.J., Teutsch S.M., Castle M., Heard R.N., and Bennetts B.H. HLA-DR,-DQA1 and -DQB1 associations in Australian multiple sclerosis patients. Eur J Immunogenet 24 2 (1997) 81-92
13. Saruhan-Direskeneli G., Esin S., Baykan-Kurt B., Ornek I., Vaughan R., and Eraksoy M. HLA-DR and -DQ associations with multiple sclerosis in Turkey. Hum Immunol 55 1 (1997) 59-65
14. Marrosu M.G., Murru M.R., Costa G., Cucca F., Sotgiu S., Rosati G., et al. Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. Am J Hum Genet 61 2 (1997) 454-457
15. Weatherby S.J., Thomson W., Pepper L., Donn R., Worthington J., Mann C.L., et al. HLA-DRB1 and disease outcome in multiple sclerosis. J Neurol 248 4 (2001) 304-310
16. Naito S., Kuroiwa Y., Itoyama T., Tsubaki T., Horikawa A., Sasazuki T., et al. HLA and Japanese MS. Tissue Antigens 12 1 (1978) 19-24
17. Gorodezky C., Najera R., Rangel B.E., Castro L.E., Flores J., Velazquez G., et al. Immunogenetic profile of multiple sclerosis in Mexicans. Hum Immunol 16 4 (1986) 364-374
18. Fogdell-Hahn A., Ligers A., Gronning M., Hillert J., and Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 55 2 (2000) 140-148
19. Prat A., and Antel J. Pathogenesis of multiple sclerosis. Curr Opin Neurol 18 3 (2005) 225-230
20. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 1 (2001) 121-127
21. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 11 (1983) 1444-1452
22. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46 4 (1996) 907-911
23. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 3 (1988) 1215
24. Olerup O., and Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39 5 (1992) 225-235
25. Allcock R.J., de la Concha E.G., Fernandez-Arquero M., Vigil P., Conejero L., Arroyo R., et al. Susceptibility to multiple sclerosis mediated by HLA-DRB1 is influenced by a second gene telomeric of the TNF cluster. Hum Immunol 60 12 (1999) 1266-1273
26. Ballerini C., Guerini F.R., Rombola G., Rosati E., Massacesi L., Ferrante P., et al. HLA-multiple sclerosis association in continental Italy and correlation with disease prevalence in Europe. J Neuroimmunol 150 1-2 (2004) 178-185
27. Coraddu F., Reyes-Yanez M.P., Parra A., Gray J., Smith S.I., Taylor C.J., et al. HLA associations with multiple sclerosis in the Canary Islands. J Neuroimmunol 87 1-2 (1998) 130-135
28. Dyment D.A., Herrera B.M., Cader M.Z., Willer C.J., Lincoln M.R., Sadovnick A.D., et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet 14 14 (2005) 2019-2026
29. Barcellos L.F., Oksenberg J.R., Begovich A.B., Martin E.R., Schmidt S., Vittinghoff E., et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 72 3 (2003) 710-716
30. Barcellos L.F., Sawcer S., Ramsay P.P., Baranzini S.E., Thomson G., Briggs F., et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 15 18 (2006) 2813-2824
31. Bland J.M., and Altman D.G. Multiple significance tests: the Bonferroni method. BMJ 310 6973 (1995) 170
32. Weinshenker B.G., and Kantarci O.H. Seeking genes for MS: big risks for big gains. Neurology 54 3 (2000) 542-544
33. Perini P., Tagliaferri C., Belloni M., Biasi G., and Gallo P. The HLA-DR13 haplotype is associated with "benign" multiple sclerosis in northeast Italy. Neurology 57 1 (2001) 158-159
34. Hensiek A.E., Sawcer S.J., Feakes R., Deans J., Mander A., Akesson E., et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 72 2 (2002) 184-187
35. Celius E.G., Harbo H.F., Egeland T., Vartdal F., Vandvik B., and Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci 178 2 (2000) 132-135
36. Weinshenker B.G., Santrach P., Bissonet A.S., McDonnell S.K., Schaid D., Moore S.B., et al. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 51 3 (1998) 742-747
37. Kantarci O.H., de Andrade M., and Weinshenker B.G. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 123 1-2 (2002) 144-159
38. Madigand M., Oger J.J., Fauchet R., Sabouraud O., and Genetet B. HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. J Neurol Sci 53 3 (1982) 519-529
39. Poser S., Ritter G., Bauer H.J., Grosse-Wilde H., Kuwert E.K., and Raun N.E. HLA-antigens and the prognosis of multiple sclerosis. J Neurol 225 3 (1981) 219-221
40. Runmarker B., Martinsson T., Wahlstrom J., and Andersen O. HLA and prognosis in multiple sclerosis. J Neurol 241 6 (1994) 385-390
41. Duquette P., Decary F., Pleines J., Boivin D., Lamoureux G., Cosgrove J.B., et al. Clinical sub-groups of multiple sclerosis in relation to HLA: DR alleles as possible markers of disease progression. Can J Neurol Sci 12 2 (1985) 106-110
42. Engell T., Raun N.E., Thomsen M., and Platz P. HLA and heterogeneity of multiple sclerosis. Neurology 32 9 (1982) 1043-1046